The vomiting reflex is coordinated by two anatomically and functionally distinct sites in the central nervous system (CNS): the chemoreceptor trigger zone (CTZ), which samples blood and cerebrospinal fluid for emetogenic stimuli, and the vomiting center, which integrates afferent signals and generates the coordinated motor output of emesis. Most antiemetic drugs work by blocking specific receptors at one or both of these sites.
The CTZ (chemoreceptor trigger zone) is located in the area postrema on the floor of the fourth ventricle. Its defining anatomical feature is that it lies outside the blood-brain barrier (BBB), meaning circulating emetogenic substances, including chemotherapy agents, uremic toxins, opioids, digoxin, and metabolic byproducts, can directly activate CTZ neurons without requiring BBB penetration. The CTZ is densely populated with D2R (dopamine D2 receptor), 5-HT3R (serotonin 5-HT3 receptor), and NK1R (neurokinin 1 receptor), making it the primary pharmacological target for antiemetics used in chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).1 Activation of the CTZ sends efferent signals to the vomiting center in the dorsal vagal complex of the medulla, which then coordinates the somatic and autonomic motor pattern of emesis.
The vomiting center, more precisely described as a central pattern generator (CPG) in the nucleus tractus solitarius (NTS) and dorsal motor nucleus of the vagus within the dorsal vagal complex, receives convergent input from four principal sources: the CTZ, the vestibular apparatus (via the vestibular nuclei, responsible for motion sickness), the GI (gastrointestinal) tract via vagal and spinal afferents (activated by local gut serotonin release from enterochromaffin cells in response to cytotoxic agents, gastric distension, or gut ischemia), and higher cortical centers (anticipatory nausea, psychological triggers). The NTS (nucleus tractus solitarius) also contains 5-HT3R and NK1R (neurokinin 1 receptor) sites, making it a second important site for antiemetic drug action.1 Emesis is generated when the CPG activates coordinated sequences including retrograde giant contractions in the small intestine, pyloric relaxation, gastric relaxation, diaphragm and abdominal wall contraction, and glottic closure.
The peripheral limb of the vomiting reflex begins in the gut mucosa, where enterochromaffin (EC) cells release serotonin in response to mechanical distension, mucosal irritation, and chemotherapy-induced cellular damage. Serotonin acts on 5-HT3 receptors on vagal afferent terminals in the gut wall, generating action potentials that travel via the vagus nerve to the NTS, activating the CPG and initiating emesis. This peripheral serotonin-mediated pathway is the primary mechanism of acute CINV within the first 24 hours of chemotherapy administration, and it is the principal target of 5-HT3 receptor antagonists (5-HT3RAs) such as ondansetron and granisetron.2 Substance P, a neuropeptide that activates NK1R (neurokinin 1 receptor) sites, mediates the delayed phase of CINV (days 2 through 5 post-chemotherapy) and is the target of NK1RA (NK1 receptor antagonist) agents such as aprepitant.
CTZ (chemoreceptor trigger zone) input: blood-borne emetogenic agents, opioids, metabolic toxins. Vestibular input: motion sickness, labyrinthine disorders. GI (gastrointestinal) vagal afferent input: enterochromaffin cell serotonin release in response to chemotherapy, distension, or mucosal injury. Cortical input: anticipatory nausea, learned associations, anxiety. Effective antiemetic therapy requires targeting the dominant input pathway for the clinical context. Chemotherapy regimens require CTZ and vagal afferent blockade; motion sickness requires vestibular pathway blockade; anticipatory nausea may require anxiolytic or behavioral approaches in addition to receptor-targeted drugs.
Prokinetic drugs enhance coordinated GI (gastrointestinal) motility by blocking inhibitory dopamine signaling in the enteric nervous system (ENS), stimulating excitatory serotonin 5-HT4 receptors (5-HT4R) on myenteric neurons, or activating motilin receptors on smooth muscle and enteric neurons. D2R (dopamine D2 receptor) signaling on enteric neurons inhibits ACh (acetylcholine) release from the myenteric plexus; D2R blockade in the gut wall disinhibits cholinergic neurotransmission, increasing antral contractile amplitude, improving antroduodenal coordination, and accelerating gastric emptying. The clinical usefulness of D2R antagonist prokinetics is substantially limited by their CNS (central nervous system) adverse effects, arising from D2R blockade in the basal ganglia and the pituitary-hypothalamic axis.
Metoclopramide is a substituted benzamide that blocks D2R in both the gut wall and the CNS, and at higher doses also blocks 5-HT3 receptors and partially activates 5-HT4R. Its central D2R blockade gives it antiemetic efficacy via the CTZ (chemoreceptor trigger zone) but also produces the full spectrum of dopamine antagonist central adverse effects: extrapyramidal symptoms (EPS) including akathisia (restlessness), acute dystonia (torticollis, oculogyric crisis), and drug-induced parkinsonism, each arising from D2R blockade in the nigrostriatal pathway.3 Tardive dyskinesia (TD), characterized by repetitive involuntary orofacial and limb movements, develops with chronic metoclopramide use and is often irreversible; it results from dopamine receptor upregulation and sensitization in the striatum after prolonged D2R blockade. The U.S. Food and Drug Administration (FDA) issued a black box warning requiring that metoclopramide not be used for longer than 12 weeks for any indication, as the risk of TD rises substantially with prolonged use.3 At the recommended dose of 5 to 10 mg three times daily before meals, metoclopramide is effective for gastroparesis and for chemotherapy-associated nausea at moderate emetogenicity levels, but its CNS risk profile requires careful patient selection and the shortest effective course.
Metoclopramide also blocks D2R in the tuberoinfundibular pathway, increasing prolactin secretion by removing dopamine's tonic inhibition of lactotrophs in the anterior pituitary. Hyperprolactinemia resulting from chronic metoclopramide use causes galactorrhea, amenorrhea, and sexual dysfunction. Additionally, metoclopramide crosses the blood-brain barrier and should be avoided in patients with Parkinson disease, in whom additional D2R blockade can worsen motor dysfunction, and in those with a history of tardive dyskinesia from any prior dopamine antagonist exposure. Drowsiness and fatigue are common at standard doses and may limit use in outpatient settings where psychomotor function is required.
Domperidone is a D2R antagonist with a distinct pharmacokinetic profile: it does not readily cross the blood-brain barrier because it is a substrate for P-glycoprotein (P-gp) efflux transport at the BBB (blood-brain barrier). This peripheral selectivity means domperidone produces prokinetic and antiemetic effects via CTZ D2R blockade (the area postrema, where it does penetrate, lies outside the BBB) and ENS D2R blockade, without the central extrapyramidal adverse effects seen with metoclopramide. The major safety concern with domperidone is QTc (corrected QT interval) prolongation due to cardiac hERG (human ether-a-go-go-related gene) potassium channel blockade; domperidone is associated with an increased risk of serious ventricular arrhythmias, particularly at higher doses and in patients with pre-existing prolonged QTc or concurrent use of other QTc-prolonging drugs.4 Domperidone is not approved for sale in the United States by the FDA but is available in Canada, Europe, and many other countries. When used, the lowest effective dose should be employed, an ECG (electrocardiogram) should be obtained to confirm baseline QTc, and concurrent QTc-prolonging drugs should be avoided.
Erythromycin at subantimicrobial doses (1 to 3 mg/kg IV or 125 to 250 mg orally before meals) acts as a motilin receptor (MTL-R) agonist on gastric smooth muscle and enteric neurons, mimicking the action of the endogenous hormone motilin that drives phase III interdigestive contractions of the migrating motor complex (MMC). Low-dose erythromycin produces powerful antral contractions and is among the most potent prokinetics available, achieving gastric emptying rates superior to metoclopramide in controlled studies.5 Its principal limitation is tachyphylaxis: motilin receptor downregulation occurs within days to weeks of continuous administration, substantially reducing prokinetic efficacy. Erythromycin is therefore most useful for acute gastroparesis (including post-surgical ileus or diabetic gastroparetic crisis) rather than for long-term outpatient management. Drug interactions include inhibition of CYP3A4 (cytochrome P450 3A4), raising plasma concentrations of cyclosporine, tacrolimus, statins, and many other CYP3A4 substrates, and additive QTc prolongation risk.
Prucalopride is a selective, high-affinity 5-HT4R agonist approved for chronic idiopathic constipation; in contrast to the non-selective 5-HT4 agonism of cisapride, prucalopride has no significant affinity for cardiac hERG channels and does not prolong the QTc interval. Cisapride, an earlier 5-HT4 agonist withdrawn from the market, caused fatal ventricular arrhythmias due to hERG blockade; prucalopride was developed specifically to retain prokinetic 5-HT4 activity without the cardiac liability.6 Prucalopride stimulates high-amplitude propagating contractions in the colon, accelerating colonic transit; its effect on gastric emptying is modest compared with D2R antagonists. It does not have clinically significant CNS activity at therapeutic doses.
The FDA (U.S. Food and Drug Administration) requires a black box warning on metoclopramide stating that it should not be used for longer than 12 weeks due to the risk of TD (tardive dyskinesia). Tardive dyskinesia results from D2R (dopamine D2 receptor) upregulation in the striatum after prolonged blockade and is often irreversible even after drug discontinuation. The risk increases with duration of use and total cumulative dose. When prescribing metoclopramide for gastroparesis, document the indication, start date, and a planned stop date. Inform patients of the risk at initiation and review at each refill.
Metoclopramide crosses the BBB (blood-brain barrier) freely – full CNS D2R (dopamine D2 receptor) blockade – extrapyramidal symptoms, tardive dyskinesia risk, hyperprolactinemia. Avoid in Parkinson disease and prior TD. Domperidone does not cross the BBB (P-gp substrate) – no extrapyramidal adverse effects – but prolongs QTc and carries arrhythmia risk. Obtain baseline ECG (electrocardiogram); avoid concurrent QTc-prolonging drugs; use lowest effective dose. Not available in the United States. For patients in the US with gastroparesis where metoclopramide is poorly tolerated, the options are limited to low-dose erythromycin (for acute use) and off-label agents.
5-HT3 receptor antagonists (5-HT3RAs) block serotonin 5-HT3 receptors (5-HT3R) on vagal afferent terminals in the gut wall and in the NTS (nucleus tractus solitarius), interrupting the peripheral serotonin-mediated afferent signal generated by chemotherapy-induced EC (enterochromaffin) cell serotonin release. They are the cornerstone of acute CINV (chemotherapy-induced nausea and vomiting) prophylaxis, defined as nausea and vomiting occurring within 24 hours of chemotherapy, and are highly effective for PONV (postoperative nausea and vomiting) as well. Ondansetron was the first clinically available 5-HT3RA and remains the most widely prescribed; granisetron, dolasetron, and palonosetron are later agents with varying pharmacokinetic profiles. Palonosetron has a substantially longer half-life (approximately 40 hours) and higher receptor binding affinity than first-generation 5-HT3RAs, and has demonstrated superior efficacy in preventing delayed CINV compared to ondansetron in clinical trials.7
The principal adverse effect of clinical importance with 5-HT3RAs is QTc (corrected QT interval) prolongation through cardiac hERG (human ether-a-go-go-related gene) channel blockade. Ondansetron has been associated with dose-dependent QTc prolongation; the FDA (U.S. Food and Drug Administration) recommends against single intravenous doses of ondansetron greater than 32 mg, as this dose was associated with significant QTc prolongation in electrocardiographic (ECG) monitoring studies.7 The concern is greatest in patients with pre-existing QTc prolongation, hypokalemia, hypomagnesemia, or concurrent use of other QTc-prolonging drugs. Palonosetron has minimal hERG channel affinity and does not cause clinically significant QTc prolongation at therapeutic doses, which is one pharmacological advantage of the newer agent. Headache and constipation are the most common non-cardiac adverse effects across the 5-HT3RA class; constipation results from 5-HT3R blockade in the ENS (enteric nervous system), which reduces the propulsive secretomotor reflex.
NK1RA (NK1 receptor antagonist) agents block substance P binding at NK1R (NK1 receptor) in the CNS (central nervous system) and periphery, targeting the delayed phase of CINV. Substance P is a neuropeptide released from central and peripheral neurons in response to chemotherapy cytotoxicity; its peak tissue concentrations and receptor-mediated effects correlate with the delayed emesis that peaks at 48 to 72 hours post-chemotherapy and persists through day 5. Aprepitant (oral) and fosaprepitant (intravenous prodrug of aprepitant) were the first approved NK1RA (NK1 receptor antagonist) agents. Netupitant is available in a fixed-dose combination with palonosetron (NEPA), combining NK1 and 5-HT3 blockade in a single oral formulation. Rolapitant is a longer-acting NK1RA with a half-life exceeding 160 hours, allowing single-dose coverage for the entire delayed CINV window.8
The drug interaction profile of aprepitant is clinically significant. Aprepitant is both a CYP3A4 (cytochrome P450 3A4) substrate and a moderate CYP3A4 inhibitor after the standard 3-day dosing course; it also induces CYP2C9 (cytochrome P450 2C9). The CYP3A4 inhibition raises plasma concentrations of CYP3A4 substrates co-administered during or shortly after the aprepitant course, including dexamethasone (the dose of dexamethasone used as an antiemetic adjunct is typically reduced by approximately 50% when co-administered with aprepitant to account for this interaction), cyclophosphamide, ifosfamide, and several other chemotherapy agents. CYP2C9 induction by aprepitant can reduce warfarin plasma concentrations; the international normalized ratio (INR) should be monitored in patients on warfarin receiving aprepitant-containing antiemetic regimens. Rolapitant does not inhibit CYP3A4, which simplifies its interaction profile relative to aprepitant.8
Guideline-concordant prophylaxis for highly emetogenic chemotherapy (HEC), including cisplatin and anthracycline-cyclophosphamide combinations, consists of three-drug combination therapy: a 5-HT3RA (5-hydroxytryptamine 3 receptor antagonist) plus an NK1RA (neurokinin 1 receptor antagonist) plus dexamethasone on day 1, followed by dexamethasone alone or combined with the NK1RA on days 2 through 4 for delayed CINV (chemotherapy-induced nausea and vomiting) coverage. When using aprepitant, reduce the dexamethasone dose to approximately 8 mg on day 1 and 8 mg on days 2 to 4 to account for CYP3A4 inhibition increasing dexamethasone exposure. Palonosetron is the preferred 5-HT3RA for this regimen based on its superior delayed CINV data.
Dopamine D2R (dopamine D2 receptor) antagonists used as antiemetics act primarily at the CTZ (chemoreceptor trigger zone) to block dopamine-mediated emetogenic signaling. Prochlorperazine, a phenothiazine antipsychotic, is commonly used for nausea and vomiting from multiple causes including chemotherapy of low to moderate emetogenicity, vestibular disorders, and postoperative nausea. It produces sedation, extrapyramidal effects including acute dystonia and akathisia, and like all phenothiazines carries a QTc prolongation risk. Promethazine, another phenothiazine, is used principally for motion sickness and PONV (postoperative nausea and vomiting); it also has significant H1 (histamine H1 receptor) antihistamine and anticholinergic activity contributing to its antiemetic effect via vestibular and CNS (central nervous system) pathways. The FDA issued a black box warning for promethazine in children under age 2, in whom it can cause fatal respiratory depression. In adults, its deep sedation and significant anticholinergic burden limit outpatient utility.9
Haloperidol, a butyrophenone D2R antagonist, is used at low doses (0.5 to 2 mg) as an antiemetic in palliative care settings and for opioid-induced nausea; it is effective at CTZ D2R blockade with a lower sedation burden than phenothiazines at antiemetic doses. Droperidol, a related butyrophenone, was widely used for PONV until the FDA issued a black box warning for QTc prolongation and risk of fatal arrhythmias in 2001; its use has declined substantially in most anesthetic practices, though it retains a place in low doses (0.625 to 1.25 mg IV) for PONV where QTc risk is assessed as acceptable. Metoclopramide, discussed in Section 2 as a prokinetic, also functions as a D2R antagonist antiemetic, particularly at higher doses used in historical chemotherapy protocols; its use as an antiemetic has been largely supplanted by 5-HT3RA (5-HT3 receptor antagonist) and NK1RA (NK1 receptor antagonist) agents for moderate- to high-emetogenicity chemotherapy.
Dexamethasone is used as an antiemetic adjunct in virtually all multimodal antiemetic regimens. Its mechanism of antiemetic action is incompletely understood; proposed mechanisms include reduction of prostaglandin synthesis in the brainstem, reduction of serotonin release from EC (enterochromaffin) cells, and reduction of blood-brain barrier permeability to emetogenic substances. Regardless of mechanism, its efficacy in both acute and delayed CINV (chemotherapy-induced nausea and vomiting) as an add-on agent is well established in randomized controlled trials (RCTs), and its addition to 5-HT3RA-based regimens consistently improves complete response rates by 15 to 25 percentage points.10 At the single-day or 3- to 4-day antiemetic doses used clinically (8 to 20 mg on day 1 of chemotherapy, then 4 to 8 mg daily for delayed CINV), dexamethasone produces transient hyperglycemia, insomnia, and mood changes; its use is generally safe for short courses even in patients with diabetes, though blood glucose monitoring and temporary insulin adjustment are appropriate.
Scopolamine is a competitive antagonist at M1R (muscarinic M1 receptor) on vestibular nucleus neurons, interrupting the vestibular afferent pathway to the vomiting center. It is the most effective single agent for motion sickness and is also used for nausea associated with labyrinthine dysfunction. The transdermal patch formulation (delivering approximately 1 mg over 72 hours) is applied behind the ear and provides sustained muscarinic blockade with systemic absorption. Adverse effects are predictable from its anticholinergic mechanism: dry mouth, blurred vision (cycloplegia), urinary retention, constipation, and confusion or sedation particularly in elderly patients. Scopolamine should be used with caution in patients with angle-closure glaucoma, benign prostatic hyperplasia, or any condition where anticholinergic burden is a concern. Hands must be washed thoroughly after handling the patch to avoid inadvertent ocular exposure, which can precipitate acute angle-closure glaucoma in susceptible individuals.
Dronabinol is a synthetic delta-9-tetrahydrocannabinol (delta-9-THC) that acts as a partial agonist at CB1 (cannabinoid receptor type 1) receptors in the CNS, including in the vomiting center and cerebral cortex, producing antiemetic and orexigenic effects. It is FDA-approved for CINV (chemotherapy-induced nausea and vomiting) refractory to conventional antiemetics and for anorexia and weight loss in patients with AIDS (acquired immunodeficiency syndrome). Its antiemetic mechanism involves CB1R (cannabinoid receptor type 1)-mediated inhibition of neurotransmitter release in vomiting pathways. Adverse effects include euphoria or dysphoria, sedation, tachycardia, dry mouth, and impaired psychomotor function; in older adults these CNS adverse effects are often poorly tolerated. Dronabinol is a Schedule III controlled substance. In contemporary oncology practice it is used as a rescue antiemetic when standard three-drug regimens fail rather than as a first-line agent, though it may provide benefit in patients who also have refractory anorexia.
CINV (chemotherapy-induced nausea and vomiting) acute phase: 5-HT3RA (5-hydroxytryptamine 3 receptor antagonist) + NK1RA (neurokinin 1 receptor antagonist) + dexamethasone. CINV delayed phase: NK1RA + dexamethasone continued. PONV (postoperative nausea and vomiting): ondansetron 4 mg IV at end of surgery +/- dexamethasone 4 mg; droperidol 0.625 mg IV as alternative. Motion sickness / vestibular nausea: scopolamine transdermal; promethazine as alternative. Opioid-induced nausea: low-dose haloperidol or prochlorperazine; metoclopramide if gastroparesis is also present. Refractory CINV / anorexia-nausea combination: dronabinol.
Gastroparesis is a syndrome of objectively delayed gastric emptying in the absence of mechanical obstruction, characterized by symptoms of nausea, vomiting, early satiety, postprandial fullness, and bloating. The two most common etiologies are diabetic gastroparesis and idiopathic gastroparesis; post-surgical gastroparesis (following vagotomy, fundoplication, or bariatric surgery) is a third important cause. In diabetic gastroparesis, chronic hyperglycemia damages the interstitial cells of Cajal (ICC), which generate gastric pacemaker activity, and damages enteric neurons and the vagus nerve via autonomic neuropathy; the resulting loss of coordinated antral contractility and pyloric relaxation impairs gastric emptying and creates the symptom complex.11 The diagnosis requires gastric emptying scintigraphy demonstrating retention of greater than 10% of a standardized radiolabeled solid meal at 4 hours after ingestion, with mechanical obstruction excluded by endoscopy or imaging.
The pharmacological management of gastroparesis is constrained by a limited number of available agents and significant adverse effect profiles for the most effective drugs. Metoclopramide 5 to 10 mg three to four times daily, taken 30 minutes before meals, is the only FDA (U.S. Food and Drug Administration)-approved drug for gastroparesis in the United States and remains the first-line pharmacological agent despite its TD (tardive dyskinesia) risk, which necessitates use at the lowest effective dose for the shortest necessary period not exceeding 12 weeks.3 In patients who respond poorly to metoclopramide or who develop intolerable adverse effects, low-dose erythromycin is a second-line option for acute exacerbations; its utility for chronic outpatient management is limited by tachyphylaxis developing within 4 weeks of continuous use. Domperidone, available through the FDA's expanded access (compassionate use) program or in countries where it is approved, may be appropriate for patients intolerant of metoclopramide who have a normal baseline QTc and no concurrent QTc-prolonging medications.
Non-pharmacological measures are integral to gastroparesis management and should always accompany pharmacological treatment. Dietary modification, specifically eating small, frequent meals of low fat and low insoluble fiber content, reduces the gastric emptying burden and improves symptoms in many patients. Tight glycemic control in diabetic gastroparesis slows the progression of autonomic neuropathy and can improve gastric emptying independent of drug therapy; acute hyperglycemia itself inhibits gastric motility and can precipitate acute gastroparetic crises. Gastric electrical stimulation (GES) with an implanted neurostimulator is an FDA-approved device therapy for medically refractory nausea and vomiting in diabetic and idiopathic gastroparesis; it primarily improves symptom burden (particularly nausea and vomiting) rather than objectively measured gastric emptying, through mechanisms involving vagal afferent modulation rather than restored contractile function.12
Acute gastroparetic crises requiring hospitalization are managed with IV (intravenous) hydration, correction of electrolyte abnormalities (hypokalemia and hypomagnesemia from vomiting are common), antiemetic therapy, and restoration of enteral nutrition by nasojejunal tube feeding when oral intake remains inadequate after initial stabilization. IV metoclopramide at 10 mg every 6 hours is standard for acute inpatient management. IV erythromycin at 1 to 3 mg/kg every 6 to 8 hours is a useful adjunct for the acute hospitalization, with the understanding that its prokinetic efficacy will diminish with prolonged use. Parenteral nutrition via central venous access is reserved for patients in whom jejunal tube feeding is not feasible; the risks of central venous catheter-associated infection and line complications make it a last resort. Reintroduction of oral intake should begin as soon as nausea and vomiting are controlled, starting with liquids and advancing to soft solids according to tolerance.
Step 1: Metoclopramide 5 mg three times daily before meals – lowest effective dose, document start date, plan for 12-week maximum. Step 2: If inadequate response or intolerable CNS (central nervous system) adverse effects, switch to low-dose erythromycin 125 to 250 mg before meals for acute exacerbations (expect tachyphylaxis within weeks). Step 3: If in a country where domperidone is available and the patient has normal baseline QTc and no concurrent QTc-prolonging drugs, domperidone 10 mg three times daily before meals is a reasonable alternative to metoclopramide. Step 4: For refractory chronic symptoms despite medical management, referral for gastric electrical stimulation evaluation is appropriate. At every step: optimize glycemic control in diabetic patients and implement dietary modification.
Hornby PJ. Central neurocircuitry associated with emesis. Am J Med. 2001;111(Suppl 8A):106S–112S.
doi:10.1016/S0002-9343(01)00849-XMinami M, Endo T, Hirafuji M, Hamaue N, Liu Y, Hiroshige T, Nemoto M, Saito H, Yoshioka M. Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol Ther. 2003;99(2):149–165.
doi:10.1016/S0163-7258(03)00057-3Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11–19.
doi:10.1111/j.1365-2036.2009.04189.xStraus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26(19):2007–2012.
doi:10.1093/eurheartj/ehi312Acosta A, Camilleri M. Prokinetics in gastroparesis. Gastroenterol Clin North Am. 2015;44(1):97–111.
doi:10.1016/j.gtc.2014.11.008Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344–2354.
doi:10.1056/NEJMoa0800089Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684(1–3):1–7.
doi:10.1016/j.ejphar.2012.01.046Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782–2797.
doi:10.1200/JCO.20.01296Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2020;131(2):411–448.
doi:10.1213/ANE.0000000000004833Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol. 2000;18(19):3409–3422.
doi:10.1200/JCO.2000.18.19.3409Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L; American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108(1):18–37.
doi:10.1038/ajg.2012.373McCallum RW, Snape W, Brody F, Wo J, Parkman HP, Nowak T. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol. 2010;8(11):947–954.
doi:10.1016/j.cgh.2010.05.020